SO YOU DRIVE to the local park for your morning walk, drive and take a Metro to your office, where you grab the lift to the third floor, and then you repeat the commute in the evening. If you have to queue up for an autorickshaw, you crib about last-mile connectivity to your doorstep, instead of walking that mile.
That’s rising urbanisation and sedentary lifestyles for you. The bane of modern India. But they are a boon for pharmaceutical companies such as Eli Lilly & Co, whose 146-year history has been powered by a list of firsts: the first treatment for pernicious anaemia, the first mass-produced antibiotic, the mass-produced Salk polio vaccine, human insulin, and pills for clinical depression and schizophrenia, among others.
Lilly is now betting that its drugs for obesity and diabetes will power its revenues into a higher trajectory. Especially as obesity and diabetes are like the proverbial chicken and egg situation: which came first? Lilly’s portfolio also has your heart covered (obesity and diabetes can get your heart).
RESPONDING TO THE DUAL CRISIS
US-based Lilly is no stranger to India. In 1993, it set up a unit to bring its treatments for diabetes, a range of cancers, osteoporosis, rheumatoid arthritis, men’s health, and growth hormone deficiency.
Now, it aims to bring to India its hugely successful drug Mounjaro that is used to treat Type 2 diabetes and as an anti-obesity drug for adults. In the US, Lilly has launched two different brands: Zepbound for obesity; and Mounjaro for Type 2 diabetes. In both, the active ingredient is tirzepatide. Mounjaro’s revenue exceeded $5 billion in 2023, its first full year on the market.
According to the FDA, approximately 70% of American adults are obese or overweight, and many of those overweight have a weight-related condition.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
"Do what's best for employees"
BEST ADVICE - PANKAJ JATHAR | CEO | NIIT LTD
Your Palate for 2025
What's in store for you in the New Year when you go out for a meal or a drink? We ask industry experts to predict F&B trends for 2025
"RBI'S STANCE SHOULD BE TO KEEP THE RUPEE MORE VOLATILE"
Axis Bank Chief Economist Neelkanth Mishra talks about the rupee, quantitative easing, the Trump impact, and more
"We should strive towards two non-zero GST rates"
Arvind Panagariya, Chairman of the 16th Finance Commission, on further reforms in the economy, the Nehruvian era and its impact on policymaking, cash transfers, and more
A GENERATION MAROONED
This generation is creating new grammar for social and professional existence. They are reimagining the very concept of work, identity, and social belonging
A TIME OF UNCERTAINTY AND OPPORTUNITY
A look at the key trends that will redefine how content will be created, distributed, and consumed
Consciousness Shaping Consumption
India has a dynamic and discerning consumer base, whose consumption pattern is experiencing a significant transformation
THE NIFTY ELEPHANTS
The composition of the Nifty 50 index has undergone notable changes in the past 30 years, with only 11 companies consistently remaining in the index. It is expected to undergo further changes in 2025 with the entry of new-age companies like Zomato
REDEFINING THE DIGITAL AGE
For Bitcoin, its future lies not as a currency but as a cornerstone of the modern financial ecosystem
THE FUTURE OF HEALTHCARE
As AI advances, so will its role in health insurance. In the future, it shall perform a variety of complex tasks, making it more accessible and aligned with individual needs
